Acetic Acid → (R)-3-(4-(1,3,4-oxadiazol-2-yl)phenylamino)-5-(1-amino-1-oxobutan-2-ylamino)pyrazine-2-carboxamide

HRID 2200457ノート

反応式

HRID 2200457 の反応式
[O:1]1[CH:5]=[N:4][N:3]=[C:2]1[C:6]1[CH:11]=[CH:10][C:9]([NH:12][C:13]2[N:18]=[C:17]([NH:19][C@H:20]([CH2:24][CH3:25])[C:21]([NH2:23])=[O:22])[CH:16]=[N:15][C:14]=2[C:26]#[N:27])=[CH:8][CH:7]=1.[OH-].[Na+].OO.CC(O)=[O:34]>CCO.CS(C)=O>[O:1]1[CH:5]=[N:4][N:3]=[C:2]1[C:6]1[CH:11]=[CH:10][C:9]([NH:12][C:13]2[C:14]([C:26]([NH2:27])=[O:34])=[N:15][CH:16]=[C:17]([NH:19][C@H:20]([CH2:24][CH3:25])[C:21]([NH2:23])=[O:22])[N:18]=2)=[CH:8][CH:7]=1

参加物

7

実験手順

The compound (R)-2-(6-(4-(1,3,4-oxadiazol-2-yl)phenylamino)-5-cyanopyrazin-2-ylamino)butanamide (57 mg, 0.156 mmol) was dissolved in EtOH (2 mL) and DMSO (1 mL), aq. 1N NaOH (1.0 mL) and aq. H2O2 (30%, 1.0 mL) were added. The mixture was stirred at room temperature for 30 min. HOAc (0.5 mL) was added. The mixture was then concentrated in vacuo. The residue was purified by HPLC to give the titled compound (3 mg). MS 383.3 (M+H); UV 204.7, 275.5, 329.8 nm; t 0.449 min.

後処理

  1. concentrationThe mixture was then concentrated in vacuo
  2. customThe residue was purified by HPLC

出典と根拠

ORDレコード
ord-19d52bda65e048dfb1519b1b896599e2
出典データセット
uspto-grants-2016_06
特許番号
US09359308B2

反応ノート

読み込み中…